13F Holdings
中文EN

KRYS Krystal Biotech, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1711279 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY26.0%
TTM net income YoY13.2%
TTM EPS YoY10.3%
Revenue 3-yr CAGR280.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin48.4%
Net margin47.9%
FCF margin66.0%
EBITDA margin49.7%

Returns

ROE17.5%
ROA15.9%
ROIC (approx.)23.0%
Asset turnover0.33x

Leverage & solvency

Liabilities / assets9.5%
Debt / equity0.00x
Current ratio7.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.44x
Accruals ratio-7.0%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20212022-12-31FY20212021-12-31
Income statement
Revenue$389.13M$290.51M$50.70M$0$0
R&D expense$58.05M$53.58M$46.43M$42.46M$27.88M
SG&A expense$146.74M$113.63M$98.29M$77.73M$40.39M
Operating income$161.29M$65.75M-$109.62M-$145.20M-$68.28M
Interest expense——$0$0$1.49M
Pretax income$189.47M$95.36M$12.90M-$139.97M-$69.57M
Income tax-$15.36M$6.20M$1.97M$0$0
Net income$204.83M$89.16M$10.93M-$139.97M-$69.57M
EBITDA$167.02M$71.72M-$104.61M-$142.55M-$66.43M
EPS (basic)7.083.120.40-5.49-3.13
EPS (diluted)6.843.000.39-5.49-3.13
Weighted avg. shares (diluted)29.95M29.74M27.75M25.49M22.20M
Balance sheet
Cash & equivalents$496.30M$344.87M$358.33M$161.90M$341.25M
Short-term investments$331.49M$252.65M$173.85M$217.27M$96.85M
Receivables$127.42M$104.75M$42.04M$0—
Inventory$40.48M$26.51M$6.99M$0—
Current assets$1.02B$742.04M$587.91M$383.78M$442.27M
PP&E, net$150.78M$155.17M$161.20M$161.68M$112.36M
Total assets$1.33B$1.06B$818.36M$558.45M$626.29M
Current liabilities$102.94M$102.00M$33.09M$28.85M$25.74M
Total liabilities$114.23M$109.46M$39.71M$36.22M$32.72M
Shareholders' equity$1.22B$946.38M$778.64M$522.23M$593.58M
Shares outstanding29.19M28.79M28.24M25.76M25.21M
Cash flow statement
Operating cash flow$200.87M$123.42M-$88.80M-$100.57M-$47.94M
Capital expenditure$11.95M$4.24M$11.80M$52.98M$68.34M
Free cash flow$188.91M$119.18M-$100.60M-$153.55M-$116.27M
Investing cash flow-$58.42M-$163.44M$82.64M-$114.08M-$226.77M
Financing cash flow$8.71M$27.01M$202.75M$35.35M$347.69M
Depreciation & amortization$5.72M$5.97M$5.01M$2.64M$1.85M
Stock-based compensation$54.51M$49.13M$39.93M$33.23M$15.32M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.